Setmelanotide (Imcivree): Uses, Evidence, and Side Effects

People living with rare genetic forms of obesity often find that diet and exercise alone do not produce lasting weight loss. Setmelanotide, sold as Imcivree, was developed to work through a specific brain pathway involved in hunger and energy use rather than as a general weight loss aid.

Key takeaways

• Setmelanotide is an MC4 receptor agonist approved under the brand name Imcivree.
• It is approved for chronic weight management in defined genetic and acquired obesity conditions, not for general obesity.
• The label does not carry a boxed warning.
• At least 27 clinical trials have studied setmelanotide, including completed and recruiting studies.
• Reported side effects in FDA data are led by nausea, off label use, and skin hyperpigmentation.

What Setmelanotide Is

Setmelanotide is a melanocortin 4 (MC4) receptor agonist, meaning it activates a receptor in the brain that helps regulate hunger, fullness, and energy expenditure. It has roughly 20-fold less activity at related melanocortin 3 and melanocortin 1 receptors, making it more selective for the pathway tied to appetite control. By reactivating MC4 receptor signaling, it is thought to reduce food intake and increase energy expenditure in people whose obesity stems from disruption of this pathway.

What Setmelanotide Is Approved For

Imcivree is approved to reduce excess body weight and help maintain that reduction over the long term. It is indicated for adults and children aged 4 years and older with acquired hypothalamic obesity, and for those aged 2 years and older with syndromic or monogenic obesity linked to Bardet-Biedl syndrome or to confirmed genetic variants in the POMC, PCSK1, or LEPR genes. Genetic testing confirming a pathogenic, likely pathogenic, or uncertain significance variant is part of the approved use for the monogenic forms. The current label does not carry a boxed warning.

What the Evidence Shows

Setmelanotide has been studied in at least 27 registered clinical trials. A completed Phase 3 open-label extension study followed patients on long-term setmelanotide treatment. An earlier completed Phase 2 trial evaluated the drug's safety and efficacy in obese participants with Prader-Willi syndrome. A newer Phase 4 study is now recruiting to examine real-world effects of MC4R agonist therapy in people with Bardet-Biedl syndrome and severe genetic obesity.

Reported Side Effects

Reports submitted to the FDA's adverse event system most commonly describe gastrointestinal and skin-related effects, led by nausea (77 reports) and vomiting (42), along with diarrhoea (38). Skin changes are also frequently reported, including skin hyperpigmentation (61) and skin discolouration (35), alongside headache (40) and fatigue (35). A notable share of reports (74) were coded as off label use rather than a specific reaction. These figures reflect the number of submitted reports, not confirmed incidence or proof that setmelanotide caused the event.